Chow Edwin Chiu Yuen, Talattof Arjang, Tsakalozou Eleftheria, Fan Jianghong, Zhao Liang, Zhang Xinyuan
Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, US Food and Drug Administration, Silver Spring, Maryland, USA.
, 10903 New Hampshire Ave., Bldg. 75, Room 4690, Silver Spring, Maryland, 20993, USA.
AAPS J. 2016 Nov;18(6):1500-1511. doi: 10.1208/s12248-016-9964-4. Epub 2016 Aug 12.
Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on C and AUC of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered C more than AUC for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered C and AUC. Reducing or increasing influx and efflux transporter activity might likely affect C and AUC of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.
药物溶解度、有效渗透率、肠道代谢及转运是决定肠道生物利用度和口服吸收的参数。然而,辅料可能通过改变这些参数来影响药物的全身生物利用度。因此,我们使用基于生理的药代动力学(PBPK)模型进行参数敏感性分析,以研究辅料对不同生物药剂学分类系统(BCS)类药物口服吸收的潜在影响。模拟结果表明,溶解度的变化对所研究的BCS 1类和3类药物的Cmax和AUC影响最小。对于BCS 1类药物,被动渗透率的变化对Cmax的影响大于对AUC的影响,但在不同的BCS 2类和3类药物中,其影响是可变的且具有药物特异性。根据BCS 1类和2类药物的化合物不同,肠道代谢活性的变化会改变Cmax和AUC。降低或增加流入和流出转运体活性可能会影响BCS 2类和3类药物的Cmax和AUC,但其影响程度可能因药物而异。BCS 2类和3类药物的被动渗透率和/或转运体活性的变化也可能对吸收分数和全身生物利用度产生显著影响,而肠道代谢活性的变化可能会影响肠道和全身生物利用度。总体而言,我们证明PBPK模型可常规用于基于理化和生理因素检查生物利用度的敏感性,进而评估速释口服固体剂型的生物豁免要求是否需要考虑辅料的影响。